Latest data show continued progress towards elimination of hepatitis C as a public health threat in England The UK Health ...

The UK Health Security Agency (UKHSA) has recently launched a genomic surveillance programme to monitor the HCV and its ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q4 2024 Earnings Call Transcript March 6, 2025 Atea Pharmaceuticals, Inc. misses on ...

Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in ...

A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.

The Inducement Grant was granted pursuant to Aligos' 2024 Inducement Plan (the "Plan”) as an inducement material to this ...

Atea Pharmaceuticals has already laid off a quarter of its workforce so far this year as the biotech prepares to launch a ...

New leadership at Seattle-area companies including Starbucks, Avanade, Tune Therapeutics, Umoja Biopharma, Siteimprove and ...

They call themselves the "Hep C Squad," and they're traveling all over Ohio with this message: Hepatitis C is curable ... to earn to be considered upper class in every US state Tesla rival ...

Results to-date demonstrate the potency of our potential best-in-class regimen with a short ... for treatment of hepatitis C virus (HCV), met its primary endpoints. Atea plans to conduct two ...

The Power of a Single Spark,” on Saturday in Cohen Auditorium. The event featured eight talks given by current Tufts students ...

R&D expenses for the year ended December 31, 2024 were $70.3 million, compared with $73.0 million for the same period of 2023. Total R&D employee-related costs reduced by $4.2 million which was ...